218 related articles for article (PubMed ID: 34917498)
1. Case Report: Evolution of
Sciumè M; Ceparano G; Eller-Vainicher C; Fabris S; Lonati S; Croci GA; Baldini L; Grifoni FI
Front Oncol; 2021; 11():734025. PubMed ID: 34917498
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis, clinical features, and treatment advances in mastocytosis.
Pardanani A; Akin C; Valent P
Best Pract Res Clin Haematol; 2006; 19(3):595-615. PubMed ID: 16781490
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
Ustun C; DeRemer DL; Akin C
Leuk Res; 2011 Sep; 35(9):1143-52. PubMed ID: 21641642
[TBL] [Abstract][Full Text] [Related]
4. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
5. FIP1L1-PDGFRA molecular analysis in the differential diagnosis of eosinophilia.
Loules G; Kalala F; Giannakoulas N; Papadakis E; Matsouka P; Speletas M
BMC Blood Disord; 2009 Feb; 9():1. PubMed ID: 19187542
[TBL] [Abstract][Full Text] [Related]
6. Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD).
Sotlar K; Colak S; Bache A; Berezowska S; Krokowski M; Bültmann B; Valent P; Horny HP
J Pathol; 2010 Apr; 220(5):586-95. PubMed ID: 20112369
[TBL] [Abstract][Full Text] [Related]
7. Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KIT.
Valent P; Cerny-Reiterer S; Hoermann G; Sperr WR; Müllauer L; Mannhalter C; Pehamberger H
Am J Blood Res; 2014; 4(2):93-100. PubMed ID: 25755909
[TBL] [Abstract][Full Text] [Related]
8. Systemic mastocytosis with
Conde-Fernandes I; Sampaio R; Moreno F; Palla-Garcia J; Teixeira MDA; Freitas I; Neves E; Jara-Acevedo M; Escribano L; Lima M
Allergy Asthma Clin Immunol; 2017; 13():21. PubMed ID: 28439288
[TBL] [Abstract][Full Text] [Related]
9. Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2013 Aug; 91(2):106-11. PubMed ID: 23621866
[TBL] [Abstract][Full Text] [Related]
10. Detection of the KIT
Craig JW; Hasserjian RP; Kim AS; Aster JC; Pinkus GS; Hornick JL; Steensma DP; Coleman Lindsley R; DeAngelo DJ; Morgan EA
Mod Pathol; 2020 Jun; 33(6):1135-1145. PubMed ID: 31896808
[TBL] [Abstract][Full Text] [Related]
11. Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management.
Pardanani A
Am J Hematol; 2023 Jul; 98(7):1097-1116. PubMed ID: 37309222
[TBL] [Abstract][Full Text] [Related]
12. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.
Pardanani A; Ketterling RP; Brockman SR; Flynn HC; Paternoster SF; Shearer BM; Reeder TL; Li CY; Cross NC; Cools J; Gilliland DG; Dewald GW; Tefferi A
Blood; 2003 Nov; 102(9):3093-6. PubMed ID: 12842979
[TBL] [Abstract][Full Text] [Related]
13. KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities.
Maric I; Robyn J; Metcalfe DD; Fay MP; Carter M; Wilson T; Fu W; Stoddard J; Scott L; Hartsell M; Kirshenbaum A; Akin C; Nutman TB; Noel P; Klion AD
J Allergy Clin Immunol; 2007 Sep; 120(3):680-7. PubMed ID: 17628645
[TBL] [Abstract][Full Text] [Related]
14. Case Report: Pediatric myeloid/lymphoid neoplasm with eosinophilia and PDGFRA rearrangement: The first case presenting as B-lymphoblastic lymphoma.
Akiely R; Almasri F; Almasri N; Abu-Ghosh A
Front Pediatr; 2022; 10():1059527. PubMed ID: 36589160
[TBL] [Abstract][Full Text] [Related]
15. Myeloid neoplasm with eosinophilia associated with isolated extramedullary FIP1L1/PDGFRA rearrangement.
Hilal T; Fauble V; Ketterling RP; Kelemen K
Cancer Genet; 2018 Jan; 220():13-18. PubMed ID: 29310833
[TBL] [Abstract][Full Text] [Related]
16. Novel approaches to treating advanced systemic mastocytosis.
Gilreath JA; Tchertanov L; Deininger MW
Clin Pharmacol; 2019; 11():77-92. PubMed ID: 31372066
[TBL] [Abstract][Full Text] [Related]
17. Precision Medicine in Systemic Mastocytosis.
Nicolosi M; Patriarca A; Andorno A; Mahmoud AM; Gennari A; Boldorini R; Gaidano G; Crisà E
Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833353
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V.
Ustun C; Corless CL; Savage N; Fiskus W; Manaloor E; Heinrich MC; Lewis G; Ramalingam P; Kepten I; Jillella A; Bhalla K
Leuk Res; 2009 May; 33(5):735-41. PubMed ID: 18986703
[TBL] [Abstract][Full Text] [Related]
19. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.
Sotlar K; Bache A; Stellmacher F; Bültmann B; Valent P; Horny HP
J Mol Diagn; 2008 Jan; 10(1):58-66. PubMed ID: 18165278
[TBL] [Abstract][Full Text] [Related]
20. KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance.
Schwaab J; Umbach R; Metzgeroth G; Naumann N; Jawhar M; Sotlar K; Horny HP; Gaiser T; Hofmann WK; Schnittger S; Cross NC; Fabarius A; Reiter A
Am J Hematol; 2015 Sep; 90(9):774-7. PubMed ID: 26017288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]